Publications by authors named "Marielle van Zutphen-van Geffen"
Article Synopsis
- Idecabtagene vicleucel (ide-cel) is an approved CAR T cell therapy for treating hard-to-treat multiple myeloma in patients who have received extensive prior treatments, and this study analyzed how effective and safe ide-cel is at different exposure levels.
- The research involved 127 patients from the phase II KarMMa study, assessing metrics like transgene levels and utilizing statistical models to examine exposure-response relationships for treatment efficacy and safety events.
- Findings indicated that higher exposure to ide-cel correlated with better response rates, especially in women and patients with specific serum protein levels, and supported a favorable benefit-risk balance within the targeted dose range of 150-450 CAR+ T
This analysis of a published study (NCT03346070) evaluated the pharmacokinetics (PKs) of sugammadex dosed by actual body weight (ABW) or ideal body weight (IBW) for reversal of moderate or deep neuromuscular block (M-NMB or D-NMB) in adults with morbid obesity. Adults with body mass index ≥ 40 kg/m , ABW ≥ 100 kg, and American Society of Anesthesiologists (ASA) Class 3 were stratified by NMB agent (rocuronium or vecuronium) and randomized 1:1:1:1:1 to (i) M-NMB, sugammadex 2 mg/kg ABW; (ii) M-NMB, sugammadex 2 mg/kg IBW; (iii) M-NMB, neostigmine 5 mg + glycopyrrolate 1 mg; (iv) D-NMB, sugammadex 4 mg/kg ABW; and (v) D-NMB, sugammadex 4 mg/kg IBW. Plasma samples for sugammadex quantification were collected predose, 2, 5, 15, 60, and 120 minutes, and 4, 6 hours postdose.
View Article and Find Full Text PDF